[Therapeutic management of menometrorrhagia in hemostasis disorders].
Numerous epidemiological studies have confirmed an association between disorder of hemostasis and menorrhagia with an incidence of von Willebrand factor deficiency of 13%, the most common underlying bleeding disorder. In this context, a multidisciplinary approach is the best model. Similarly, women using anticoagulant treatment are exposed to menorrhagia or metrorraghia. The research of both gynaecological disease and therapeutic overdose is necessary.
Plu-Bureau
G
G
Unité de gynécologie endocrinienne.
Horellou
M-H
MH
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000150:complications*; D005260:Female; D006801:Humans; D008796:Metrorrhagia / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy*; D014842:von Willebrand Diseases / Q000150:complications / Q000453:epidemiology
D000925:Anticoagulants